tbuckley/cabot-search huggingface dataset:
An Address Delivered at the Opening of the Section of Ophthalmology
Authors: N. C. MacNamara
Journal: BMJ (1891)

islands does phtliisis least prevail ?WVhere is oxidation so keen that gout is burnt ancd purged away ?Let us know wlat diseases are p)romoted and what are prohibited by the qenius loci; let us take the great forces of external Nature into our conifidence, and we slhall be able to control disease by greater agencies tllan tlle druggist can supply.
Associations between receipt of a treatment summary, emotional concerns, and patterns of care among post-treatment cancer survivors.
Authors: Ruth Rechis, Stephanie Nutt, Ellen Burke Beckjord
Journal: Journal of Clinical Oncology (2012)

52 Background: Treatment summaries (TS), a critical component of survivorship care plans, were identified as a tool to improve long-term outcomes for the 12 million cancer survivors alive in the United States. Methods: In 2010, the Lance Armstrong Foundation fielded the LIVESTRONG Survey for People Affected by Cancer. Respondents were recruited through several channels including partnerships with national organizations such as ASCO. Over a 9-month period, 12,682 people completed the survey, including 3,682 post-treatment cancer survivors (PTCS). The survey addressed post-treatment concerns including receipt of TS. Full survey results were presented at the 2011 ASCO Annual Meeting. Results: Receipt of TS data was available for 3,042 PTCS: average age (50); female (65%); average time since diagnosis (6 years); received a TS (34%). PTCS who received TS reported that they were closer to time since diagnosis or since treatment ended (p &lt; 0.01); more likely to have received chemotherapy (p &lt; 0.01); more often receiving the majority of their health care from a medical oncologist (p &lt; 0.05); experiencing significantly fewer (p &lt; 0.05) post-treatment emotional concerns (including emotional distress; fears of recurrence; concerns about family risk; and appearance concerns) and were more likely to have received care; significantly less likely to say that they had “learned to live with” their concerns (p &lt;0.05)—the most common reason among participants for not receiving care. Finally, receipt of a TS was related to higher information efficacy (p &lt; 0.01; which appeared to mediate the relationship between receipt of a TS and fewer emotional concerns). PTCS who received a TS more often reported that their needs were met including information received about possible late-effects; care they got during treatment; and care they received after treatment. Conclusions: These results support the provision of TS to PTCS. Receipt of TS was associated with a variety of positive outcomes; however, only about one-third of PTCS received one. Future studies focused on patient perspectives on care planning tools, such as treatment summaries and care plans, can help to improve optimal survivorship care delivery.
Indoor Firing Ranges Pose Lead Exposure Risk
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE SIGNIFICANCE OF LEUCOCYTOSIS IN SURGICAL DIAGNOSIS.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ocular histoplasmosis
Authors: Dhir S, Talwar P, Jain I
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NECROLOGY.
Authors: J. J. Bland
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Values in Table
Journal: JAMA (2021)

Łucja Bieleninik, PhD; Monika Geretsegger, PhD; Karin Mössler, Drscmus; Jörg Assmus, PhD; Grace Thompson, PhD; Gustavo Gattino, PhD; Cochavit Elefant, PhD; Tali Gottfried, PhD; Roberta Igliozzi, PhD; Filippo Muratori, MD; Ferdinando Suvini, MA; Jinah Kim, PhD; Mike J. Crawford, MD; Helen Odell-Miller, PhD; Amelia Oldfield, PhD; Órla Casey, MA; Johanna Finnemann, MRes; John Carpente, PhD; A-La Park, MSc; Enzo Grossi, MD; Christian Gold, PhD; for the TIME-A Study Team
Free Papers
Authors: R. Piccione, R. Martini, V. Nappi, S. Spedicato, C. Uguccioni, M. J. Volpini, M. Nastasi, S. Campagna, H. Reinelt, G. Fischer, H. Wiedeck, G. Steinbach, M. Georgieff, P. Radermacher, B. Santak, J. Adler, T. Iber, O. Väisänen, I. Parviainen, M. Hippeläinen, E. Berg, H. Hendolin, E. Ruokonen, J. Takala, T. S. Walsh, P. Hopton, A. Lee, G. Kostopanagiotou, N. Arkadopoulos, K. Theodoraki, L. Athanassiou, A. Prahalias, V. Smimiotis, J. Papadimitriou, R. Imberti, M. Vairetti, M. Gualea, F. Feletti, I. Preseglio, G. Bellinzona, P. Richelmi, M. Autelli, D. De Backer, J. Créteur, N. Smail, O. Noordally, B. Gulbis, R. J. Kahn, J. L. Vincent, D. Tighe, R. Moss, D. Bennett, P. F. Laterre, D. Schmidlin, E. Danse, J. Pelgrim, B. Espeel, C. Guinotte, M. S. Reynaert
Journal: Intensive Care Medicine (1996)
The Voice Governor: Give It a Chance. Correct Body Mechanics Does it
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug use and expenditures in 1982
Authors: C. Baum
Journal: JAMA (1985)

This article provides national estimates of drug use and drug expenditures in 1982. Total outpatient drug exposure increased 5% from 1981 to 1982 and 28% from 1971 to 1982. Hydrochlorothiazide was the most frequently dispensed drug chemical and was contained in more than 5% of all 1982 prescriptions. Sixteen major therapeutic classes accounted for about 80% of drugstore and hospital expenditures for ethical pharmaceuticals. Hospitals spent around $3.0 billion and a third of this total was for anti-infectives administered for systemic effects. The prescription drug component of the consumer price index increased 11.7% in 1982, and consumers spent about $14.5 billion on prescriptions from retail pharmacies alone. (<i>JAMA</i>1985;253:382-386)
THE ADMINISTRATION STUDIES SOCIAL INSURANCE
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phenylbutazone
Authors: H. A. Reid
Journal: BMJ (1954)

<h3>Summary</h3> <h3>Background and objectives</h3> Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease that was first recognized in children but also affects adults. This study assessed the disease presentation and outcome in a nationwide cohort of patients with aHUS according to the age at onset and the underlying complement abnormalities. <h3>Design, setting, participants, &amp; measurements</h3> A total of 214 patients with aHUS were enrolled between 2000 and 2008 and screened for mutations in the six susceptibility factors for aHUS and for anti–factor H antibodies. <h3>Results</h3> Onset of aHUS occurred as frequently during adulthood (58.4%) as during childhood (41.6%). The percentages of patients who developed the disease were 23%, 40%, 70%, and 98% by age 2, 18, 40, and 60 years, respectively. Mortality was higher in children than in adults (6.7% versus 0.8% at 1 year) (<i>P</i>=0.02), but progression to ESRD after the first aHUS episode was more frequent in adults (46% versus 16%; <i>P</i>&lt;0.001). Sixty-one percent of patients had mutations in their complement genes. The renal outcome was not significantly different in adults regardless of genetic background. Only membrane cofactor protein (MCP) and undetermined aHUS were less severe in children than adults. The frequency of relapse after 1 year was 92% in children with MCP-associated HUS and approximately 30% in all other subgroups. <h3>Conclusion</h3> Mortality rate was higher in children than adults with aHUS, but renal prognosis was worse in adults than children. In children, the prognosis strongly depends on the genetic background.
SI Units for Clinical Laboratory Data
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Reference Directories
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is Medical School the Right Place to Choose a Specialty?
Authors: S. Schafer
Journal: JAMA (2001)

THE OPPORTUNITY TO GAIN exposure to the various fields of medicine en route to selecting a specialty.Each spring, the residency match process lights a fire under senior medical students.Interviewing applicants and residencies evaluate and rank each other prior to final placement by the National Residency Matching Program (NRMP).At many schools, the culminating event is a Match Day ceremony, where seniors gather to learn whether their efforts have merited entry into their program of choice.The agony and ecstasy of medical school crystallize into a single moment as the seal is broken on the envelope holding each graduate's match outcome.The result is met with elation and relief for many, disappointment for some.Most feel satisfaction at advancing closer to a career, perhaps mingled with regret at leaving other options behind.Even amid the jubilation, an undercurrent of anticipation and trepidation is palpable at the prospect of assuming real responsibilities.In 2001, 93.7% of graduating allopathic US medical students matched into residency, accounting for 73.8% of the 18354 positions filled by the NRMP. 1 An additional 4215 positions were filled by US osteopathic applicants, US international medical graduates (IMGs) and non-US IMGs.Overall, available positions in primary and specialty care both showed an 89% fill rate, although entry into primary care was down 3.6% compared to 2000. 1 Residency training is a relatively new development in medical education. 2 In the early 1900s, medical school was considered adequate preparation for general practice.Expansion of information by the 1920s necessitated a "rounding out" year of internship.Specialty training (a privilege reserved for only the most promising candidates) was also launched around this time.Required to live on hospital grounds, these intrepid and typically unpaid souls were aptly dubbed "residents."Although much of their time was spent caring for patients, resident physicians also languished in laboratory and custodial work.The process could take many years, advancement was arbitrary, and attrition was high.Some physicians eschewed this pathway and sought specialty training abroad; others proclaimed themselves specialists after brief, unregulated study.The quality of postgraduate education varied widely.The lack of standardization was addressed in the 1930s with the establishment of many specialty boards.By the 1950s, residents exceeded medical students in number and specialist physicians exceeded generalists.A match plan (similar to today's) was established in 1951.Further refinements included salaries for residents and relaxation of rules pertaining to personal life.The 1970s saw merging of internship and residency as well as proliferation of subspecialty and fellowship training.Electronic application was recently introduced.How will the residency selection process continue to evolve?jms060601f1scan
DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas—Final results.
Authors: Thomas Jens Ettrich, Lukas Perkhofer, Volker Kaechele, Andreas W. Berger, Melanie Guethle, Rainer Muche, Goetz von Wichert, Thomas M. Gress, Patrick Michl, Michael Geissler, Holger Frithjof Hebart, Petra Buechner-Steudel, Thomas Seufferlein
Journal: Journal of Clinical Oncology (2015)

4122 Background: Pancreatic ductal adenocarcinoma still remains a major cause of cancer related deaths in the western world. The current study was conducted to confirm the activity and feasibility of docetaxel/ oxaliplatin combination in 2nd-line treatment of advanced pancreatic ductal adenocarcinoma. Methods: Prospective single arm, non-randomized, multi-center, Simon’s two stage phase II trial using docetaxel (75 mg/m2, 60 min, d 1) and oxaliplatin (80 mg/m2, 120 min, d 2) in 21-day cycles. Duration of the trial was scheduled up two 8 cycles. Primary endpoint was tumor response according to RECIST 1.0. Secondary endpoints were progression free survival, overall survival, safety/toxicity, QoL and clinical benefit. Results: Data represents the intention to treat analysis of 44 patients included between 2008 and 2012. The majority of patients received a gemcitabine based first-line chemotherapy (95.5%). The primary endpoint of tumor response was achieved in 15.9% (7 partial remissions, no complete remission), with a disease control rate of 48% after the first two treatment cycles. Median progression free survival was 7 weeks (CI 6-15.9 weeks) and overall survival 40 weeks (CI 20.4-56.4 weeks). No unexpected adverse events occured. The recorded AEs were mainly hematologic (neutropenia grade 3/4 63.6%, febrile neutropenia 4.6%), gastrointestinal (29.6% grade 3/4 AEs) and infectious (18.2% grade 3/4 AEs). Conclusions: In this single-arm 2nd-line trial for the treatment of advanced PDAC, the combination of docetaxel and oxaliplatin shows promising results comparable with other 2nd-line protocols such as OFF (oxaliplatin, 5-FU, leucovorin) or liposomal irinotecan (MM-398) plus 5-FU/leucovorin (NAPOLI 1-trial). Some patients seem to benefit particularly as indicated by long periods of treatment in this setting. Even after 8 cycles of treatment with DocOx, partial response was observed in 2 patients and stable disease in another 6 patients corresponding to a disease control rate of 18%. The toxicity profile was quite tolerable and comparable to other 2nd-line studies. Clinical trial information: NCT00690300 Clinical trial information: NCT00690300.
Highlights
Authors: Howard Bauchner, Roger Rosenberg, Jeffrey Saver
Journal: JAMA (2014)

Ambulance-Based Thrombolysis in Acute Ischemic Stroke 1622Early thrombolysis with intravenous tissue plasminogen activator is associated with better outcomes in acute ischemic stroke.In a study randomized by week from May 1, 2011, to January 31, 2013, that involved 6182 German adults with suspected stroke, Ebinger and colleagues found that compared with conventional ambulance care, use of an ambulance equipped with a computed tomography scanner, laboratory capability, telemedicine connection, and trained stroke team resulted in decreased time to treatment without an increase in adverse events.In an Editorial, Grotta discusses progress in treatment of ischemic stroke.